Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Sean Dowdy, MD
Published Online: Monday, Jun 09, 2014


Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.



Online CME Activities
TitleExpiration DateCME Credits
PARP Inhibitors: Current and Future Options for Breast and Ovarian CancerJun 20, 20161.0
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic CancersJul 31, 20162.5